A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic oncology candidates, while allowing prospective partners to access the technology platform through selected R&D collaborations. Alacrita was asked to help create a detailed early clinical plan for the company's lead asset, to be used as a foundation piece of the business strategy.
Our oncology consultant created a detailed timeline and gap analysis for the company’s initial IND filing and Phase 0-l clinical trial launch.
This involved:
Our consultant presented to the Board and was retained as an ongoing medical advisor to the company.
Leverage the skills and experience of our seasoned drug development physicians to refine your clinical strategy and operations.